BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cell News » Page 131

Stem Cell News

BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.

As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.

Cytori Completes Enrollment for Habeo™ Cell Therapy for Scleroderma and Impaired Hand Function

By Leave a Comment

  • Cytori developing cell therapies that harness the unique attributes of adipose-derived regenerative cells (ADRCs)

  • 40 patients enrolled among 5 French centers: Marseille, Montpelier, Rouen, Lyon, and Paris

SAN DIEGO, Jan. 22, 2018 — Cytori Therapeutics, Inc. (NASDAQ:CYTX) announces completion of patient enrollment in SCLERADEC II (NCT02558543), a randomized, double-blind, placebo-controlled, parallel group, multi-center clinical trial intended to study the safety and efficacy of Habeo™ Cell Therapy in up to 40 subjects with impaired hand function due to scleroderma (systemic sclerosis). [Read more…]

Gilead Sciences and Kite Expand CAR-T Domination with Acquisition of Cell Design Labs

By Leave a Comment

— Adds Two Technology Platforms that May be Broadly Applicable in Cellular Therapy —

— Enables Research and Development of Potential Future Generations of CAR T and TCR T-cell Therapies for Solid Tumors —

Cell Design LabsFOSTER CITY, Calif. & SANTA MONICA, Calif.–Dec. 7, 2017–Gilead Sciences, Inc. (Nasdaq: GILD) and its cell therapy subsidiary Kite announced that they have entered into a definitive agreement under which they have agreed to acquire Cell Design Labs, Inc., gaining new technology platforms that will enhance research and development efforts in cellular therapy.

Under the terms of the agreement, Gilead will acquire all of the outstanding shares of Cell Design Labs, which includes the approximately 12.2 percent of shares of Cell Design Labs that are currently held by Kite, for up to approximately $567 million. The agreement includes an initial upfront payment of approximately $175 million, subject to certain adjustments, and additional payments of up to $322 million that will be paid to the shareholders of Cell Design Labs other than Kite upon the occurrence of certain events, including the achievement of development and approval milestones. The acquisition is subject to customary closing conditions, and is expected to close shortly. [Read more…]

J&J to Compete in CAR-T: Subsidiary Janssen Biotech Signs $350M Deal with Legend Biotech

By Leave a Comment

Janssen Enters Worldwide Collaboration and License Agreement with Chinese Company Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy

HORSHAM, Pa., Dec. 21, 2017 — Janssen Biotech, Inc. (“Janssen”), a Janssen Pharmaceutical Company of Johnson & Johnson, announced today that it has entered into a worldwide collaboration and license agreement with Legend Biotech USA Inc. and Legend Biotech Ireland Limited (“Legend”), subsidiaries of Genscript Biotech Corporation, to develop, manufacture and commercialize a chimeric antigen receptor (CAR) T-cell drug candidate, LCAR-B38M, which specifically targets the B-cell maturation antigen (BCMA). LCAR-B38M is currently accepted for review by the China Food and Drug Administration (CFDA) and in the planning phase of clinical studies in the United States for multiple myeloma. [Read more…]

Magenta Therapeutics’ Expanded Stem Cell Product, MGTA-456, Engrafts in 100% of Patients

By Leave a Comment

– Data show rapid and durable engraftment with MGTA-456, an expanded cord blood stem cell product, in all 18 patients with hematologic malignancies across all conditioning regimens tested –
– MGTA-456 achieves clinical benefits of cord blood transplant –
– Clinically validated process to expand the numbers of CD34+ cells by >300 fold in single cord blood units significantly increases probability of identifying better HLA-matched stem cell donors for patients

Magenta Therapeutics - Cord Blood ExpansionDecember 11, 2017, CAMBRIDGE, Mass.–Magenta Therapeutics, a biotechnology company developing therapeutics to improve and extend the use of curative bone marrow transplant for more patients, today reported Phase 2 clinical data from its MGTA-456 hematopoietic stem cell (HSC) expansion program at the 59th annual meeting of the American Society of Hematology (ASH) in Atlanta, Ga. MGTA-456 is a single umbilical cord blood unit expanded with an aryl hydrocarbon receptor (AHR) antagonist. It is currently being studied in adult and pediatric patients with hematologic malignancies.

[Read more…]

Gladstone Institutes Initiates Research Collaboration With Eli Lilly for Neurodegenerative Diseases

By Leave a Comment

Study will use innovative technology to focus on neurodegenerative diseases

Gladstone and Eli Lilly
Steve Finkbeiner, M.D., Ph.D., Senior Investigator, Gladstone Institute of Neurological Disease

SAN FRANCISCO, December 7, 2017 (Newswire.com) – The Gladstone Institutes announced today a new research collaboration with Eli Lilly and Company focused on neurodegenerative diseases. This multi-year, milestone-driven project will be based on a combination of innovative technologies developed at Gladstone by Steve Finkbeiner, M.D., Ph.D. His laboratory will work closely with Lilly during this collaboration.

“This collaboration has high potential to open new avenues towards effective therapies for neurodegenerative diseases,” said Gladstone President R. Sanders Williams, M.D. “Both organizations are committed to meeting this major unmet need.”

Key to the project is a robotic microscope system developed in Finkbeiner’s laboratory with funds from Gladstone, the Taube/Koret Center for Neurodegenerative Disease Research, and the ALS Association. This fully automated platform allows scientists to track thousands of individual cells for days or weeks at a time, and follow discrete cellular functions.

When coupled with neurons generated from induced pluripotent stem cells collected from patients with neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and ALS, this microscope becomes a powerful tool to study the cells and their responses to disease and treatments. [Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0